Group of research subjects receiving same treatment.
1The last five days of each study arm were used for data analysis.
2Post hoc group division did not affect median OS in either study arm.
3Pathologists and centralized pathology were blinded to the patients' study arm.
4Patients in the Zevalin study arm experienced longer progression-free survival compared to other patients.
5Oh yes, certainly; and you had better get the study arm-chair for your uncle.
6Each study arm included 25 villages randomly assigned to one of the six treatment arms.
7In both study arm, depression and anxiety scores declined over the duration of the study.
8Results: The 79 patients in each study arm each showed no significant difference in preoperative parameters.
9Results: Forty-two and 43 patients were randomly assigned to a study arm and a control, respectively.
10The parent-reported outcomes, collected daily during hospitalization and at home, will be compared by study arm.
11There were one major and two minor complications in each study arm but no clinically evident stroke.
12Differences between arms were assessed by linear mixed effects modeling, with time and study arm as independent variables.
13Weight change × study arm interaction was associated with significant improvement in body image from baseline to six months.
14Locoregional disease control was observed in 44% in study arm and 32% in control arm of patients.
15Interventions: The CGMS was applied for 72 hours after 1 month and at the end of each study arm.
16Control subjects were matched to each case subject on NBSS study arm, screening center, year of birth, and age at diagnosis of benign breast disease.